Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Nanoliposomal irinotecan

EU orphan designation number: EU/3/11/933   
Active ingredient: Nanoliposomal irinotecan
Indication: Treatment of pancreatic cancer
Sponsor: Merrimack Pharmaceuticals UK Limited
c/o Wilmer Cutler Pickering Hale and Dorr LLP, Alder Castle, 10 Noble Street, London EC2V 7QJ, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/12/2011 Centralised Orphan - Designation EMA/OD/051/11 (2011)9419 of 09/12/2011